Back to top
more

OpGen (OPGN)

(Delayed Data from OTC)

$1.75 USD

1.75
321

0.00 (0.00%)

Updated Nov 5, 2024 12:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Establishment Labs (ESTA) delivered earnings and revenue surprises of 10.77% and 4.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Bright Health Group (BHG) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Bright Health (BHG) delivered earnings and revenue surprises of -63.17% and 61.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Buy 5 Top-Ranked Stocks With Rising P/E in July

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).

Sanghamitra Saha headshot

Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns

by Sanghamitra Saha

Do you have more faith in DuPont analysis than simple ROE calculation? Tap PDD Holdings Inc. (PDD), OpGen (OPGN), AGCO (AGCO), A10 Networks (ATEN) and The Duckhorn Portfolio (NAPA).

Sanghamitra Saha headshot

Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).

Sanghamitra Saha headshot

Go Beyond Bargain Hunting, Buy 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), Horizon Technology Finance (HRZN), Equity Commonwealth (EQC), NOV (NOV) and Spartacus Acquisition (NN).

Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics

by Zacks Equity Research

Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.

Sanghamitra Saha headshot

Forget Bargain Hunting, Buy 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).

Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 76.92% and 8.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LHC Group (LHCG) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

LHC (LHCG) delivered earnings and revenue surprises of -25.76% and 3.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -11.54% and 2.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OpGen, Inc. (OPGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 0.00% and -22.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -31.82% and -50.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates (Revised)

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -20.69% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -6.90% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 13th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.